Objective: We evaluated the effects of platforms, size filter cutoffs, and targeted regions of cytogenomic microarray (CMA) on the detection of copy number variants (CNVs) and uniparental disomy (UPD) in prenatal diagnosis.
| INTRODUCTION
The clinical application of cytogenomic microarray (CMA) in prenatal diagnosis has been a subject of discussion for more than a decade.
Numerous publications have confirmed its clinical utility in generating a higher detection rate than conventional cytogenetic methods. [1] [2] [3] The functional resolution and the sensitivity of an array are determined by the types of probes used, probe spacing, the number of consecutive probes needed to confidently identify a true copy number variant (CNV), and size filter cutoffs used in data analysis.
On the basis of the American College of Medical Genetics and
Genomics (ACMG) standards and guidelines of 2013, the design of both prenatal and postnatal CMA whole-genome array platforms should allow for detection of both gains and losses of 400 kb or larger. 4 To minimize the detection of variants of uncertain clinical significance (VOUS), some clinical laboratories offering prenatal CMA have chosen either to reduce the densities of the backbone probes 5 or to apply strict reporting criteria that limit gains or losses in the backbone to 1 Mb or larger. 1 A recent study demonstrated that clinically relevant CNVs of less than 500 kb could be potentially missed with these approaches in postnatal CMA analyses. In that study, 24 (44%) of 54 genes associated with single-gene deletions were located in the nontargeted genomic regions; these included 24 with well-characterized haploinsufficiency, 16 genes with evidence of dosage sensitivity, 1 gene with intragenic dominant-negative deletion, 1 recessive gene, and 12 chromosome X-linked Online Mendelian Inheritance in Man (OMIM) morbid genes. 6 Thus, the platform design of targeted and nontargeted regions, as well as the size filter cutoff settings used for data analysis, can affect the detection of CNVs for prenatal CMA. In a cohort of prenatal cases submitted for testing at a clinical reference laboratory, we first investigated the detection of CNVs by using a high-resolution oligo-single nucleotide polymorphism (SNP) CMA platform with a comparatively small size filter cutoff. The interpretation of a CNV's clinical significance was based on a five-tiered classification system, using ACMG definitions. 7 Next, we evaluated the hypothetical impact on detection of CNVs in the cohort by using the same or other CMA platforms with a number of example combinations of size filter cutoffs in data analysis.
| MATERIALS AND METHODS

| Patients
The cohort comprised deidentified results from 5026 consecutive pre- 74% of AF studies were performed using direct (uncultured) specimens, and 26% were completed using cultured specimens. Approximately 42% of CVS studies were performed using uncultured specimens, and 58% were analyzed using cultured specimens. On the basis of the indi- 
| Interpretation and reporting
The interpretation of CNV results was based on a five-tiered classification system, using ACMG definitions: (1) What's already known about this topic?
• Cytogenomic microarray (CMA) generates a higher detection rate than conventional cytogenetic methods in prenatal diagnosis.
• In prenatal CMA, the detection of CNVs and UPDs may be affected by different combinations of platforms, size filter cutoffs, and targeted regions for data analysis.
What does this study add?
• This study revealed a 4% increase in detection rate above that of traditional karyotyping.
• The hypothetical decrease in detection of CNVs and
UPDs ranged from 3.8% to 23.0%, depending on the combinations of platform and size filter cutoff used in data analysis.
• For the subgroup of pathogenic and likely pathogenic CNVs < 1 Mb, the hypothetical decrease of detection ranged from 2.7% to 24.3%.
for copy number changes). Large cutoffs (≥1000 kb) were used for both gains and losses in nontargeted regions, and small cutoffs (≥20 kb) were used for both gains and losses in targeted regions. Platforms B and C used the relatively low-resolution Agilent CGH plus SNP microarray (180 and 400 K) with different combinations of large cutoffs (≥500-1000 kb for losses and ≥1000-2000 kb for gains) in nontargeted regions and relatively small cutoffs (≥50-100 kb for losses and ≥50-200 kb for gains) in targeted regions. Platform D used the high-resolution Affymetrix CytoScan HD array with large cutoffs (≥1000 kb for losses and ≥2000 kb for gains) in nontargeted regions and small cutoffs (≥50 kb) for both gains and losses in targeted regions. Platform E used the high-resolution Agilent CGH array (1 M) with large cutoffs (≥1000 kb for losses and ≥2000 kb for gains) in nontargeted regions and small cutoffs (≥50 kb) for both gains and losses in targeted regions. Platform F used the low-resolution Agilent array (44 k) with large cutoffs (≥500 kb for losses and ≥1000 kb for gains) in nontargeted regions and relatively large cutoffs (≥200 kb for losses and ≥500 kb for gains) in targeted regions. Platform G used high-resolution Affymetrix CytoScan HD array with large cutoffs (≥1000 kb for losses and ≥2000 kb for gains) in nontargeted regions and larger cutoffs (≥200 kb for losses and ≥500 kb for gains) in targeted regions. To estimate the detection rate using different CMA platforms and size filter cutoffs, we applied the type and spacing of the probes and size filter cutoff specifications of each platform to the CNVs and UPDs detected using our current assay. The iso/heteroUPD9 revealed mosaic trisomy 9, and two of the iso/heteroUPD15 showed mosaic trisomy 15, which suggests that trisomy rescue was involved in the formation of UPD in these three cases.
| Mosaic findings and follow-ups
Of the 51 cases with mosaic CMA findings, 41 were studied from AF Figure 3 ). Among the cases with balanced rearrangement, only one with a balanced translocation had an abnormal CMA result, 
| Detection of small (<1 Mb) pathogenic and likely pathogenic CNVs
Of the 157 pathogenic CNVs smaller than 10 Mb ( Figure 2B and Table 2 The smallest deletion was identified in a family with parental relatedness and a known family history of extremely small heterozygous 
| Estimated impact of platform and size filter cutoffs on detection of CNVs and UPDs
We evaluated the hypothetical effects on CNV and UPD detection of varying the size filter cutoff with our current platform and two other CMA platforms (Figure 4 and Tables 4 and S4 ). The analysis was limited to pathogenic and likely pathogenic CNVs, VOUS, and UPD (n = 808). Using alternative platforms with the same or lower probe density and smaller or larger size cutoffs for simulating data analysis detected 622 to 777 variants, equating to an estimated reduction of overall detection rate by 23.0% to 3.8% ( Figure 4A ). In the cases with pathogenic or likely pathogenic findings (including UPD) using our current assay (n = 562), the detection ranged from 527 to 559 variants, a decline in detection rate of 6.2% to 0.5% ( Figure 4B ). When pathogenic and likely pathogenic CNVs smaller than 1 Mb (n = 37) were counted, the detection ranged from 28 to 36 variants, equating to a reduction of 24.3% to 2.7% ( Figure 4C ).
| DISCUSSION
In this cohort of 5026 predominantly high-risk pregnancies, we identified a 4% increase in detection rate compared with that of standard chromosome analysis through karyotyping. This falls within the ranges from previously published cohorts. 14 However, it is substantially higher than that reported from two meta-analyses (2.5 and 2.9%) 1, 15 .
It is also consistent with a previous finding that when karyotyping is normal, CMA has a statistically higher chance of identifying pathogenic CNVs in cases with abnormal ultrasound compared with cases without abnormal ultrasound as an indication. 16 The VOUS reporting rate (4.6%) in this study is consistent with that of other Table 4 ). In addition, applying a platform of lower resolution but with smaller size filter cutoffs as used in the paper published by Hollenbeck et al, 6 the detection did not critically decrease ( Table 4 ).
The size filter cutoffs used in this study were mainly for purposes of data analysis, and not for reporting criteria, which are independently decided by different laboratories. When using a high- nontargeted genomic regions. 6 In comparison, in our study, the majority of the identified microdeletions and microduplications were The clinical significance of small (<500 kb) deletions or duplications involving only one or a few genes was often interpreted as uncertain in our study (Table S1 ). Furthermore, when the targeted region is sensitive to copy number loss only, the clinical significance of copy number gain is often uncertain.
Moreover, how laboratories interpret results for CNVs with reduced penetrance and variable expressivity will also affect variant classification and detection rate. 10, 18 In this cohort, we found that approximately 2% (103 of 5026) had a result associated with reduced penetrance and variable expressivity (including 47 pathogenic, 7 likely pathogenic variants, and 49 VOUS; Data S2). Some laboratories may elect not to report variants with penetrance below a certain level, such as risk loci with penetrance 18 less than 25%.
Others may choose to report all variants detected. It is impossible in the prenatal setting to predict the phenotypic outcome in children with these risk loci, 18 and providing families with opt-out options for certain types of CMA information would be very difficult in actual practice given time limitations and the complexity of some CMA results. A recent study evaluating pregnant women's preferences regarding prenatal testing for microdeletion and microduplication conditions demonstrated that not all the conditions were considered to be equal and that prenatal testing for these conditions is not always deemed an all-or-none process. 20 At present, the most common approach related to CMA result disclosure is to reveal all clinical relevant or potentially relevant information including VOUS and results associated with reduced penetrance, 18 because even uncertain findings may be associated with a condition that may manifest later in life. Clinicians ordering CMA testing should understand that they may receive potentially clinical relevant but uncertain findings, including results related to rare or nonrecurrent CNVs, for which there is incomplete understanding of a phenotype due to the lack of comprehensive genotype-phenotype studies for many loci.
In conclusion, our findings demonstrated the choices of platform, size filter cutoffs, and targeted/nontargeted regions can significantly affect CNV and UPD detection rate in prenatal CMA. An updated and detailed clinical guideline for prenatal CMA analysis is recommended to provide a more detailed and comprehensive set of requirements for CMA platforms with regard to resolution and regions should be targeted. Guideline updates should also address whether and how to report CNVs in genomic regions with reduced penetrance. Updated guidelines for prenatal CMA analysis have the potential to improve reporting accuracy and decrease variability among testing laboratories, which will ultimately benefit critical decision making during pregnancy.
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